Skip to content
lifestyle.friendhood.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Insilico Medicine
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
July 22, 2026
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
July 14, 2026
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
July 12, 2026
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
July 8, 2026
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
July 7, 2026
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
July 1, 2026
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
June 22, 2026
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
June 17, 2026
Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
April 28, 2026
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
April 24, 2026
←
Previous Page
1
2
3
Next Page
→